Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Baylor College of Medicine |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00608478 |
RATIONALE: Gene-modified T lymphocytes may help the body build an effective immune response to kill cancer cells. Monoclonal antibodies, such as anti-CD45 monoclonal antibody, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving T lymphocytes together with CD45 monoclonal antibody may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of T lymphocytes when given together with anti-CD45 monoclonal antibody in treating patients with relapsed Epstein-Barr virus-associated Hodgkin lymphoma, non-Hodgkin lymphoma, or lymphoproliferative disorder.
Condition | Intervention | Phase |
---|---|---|
Lymphoma Lymphoproliferative Disorder |
Drug: anti-CD45 monoclonal antibody Drug: autologous LMP1-/LMP2- specific cytotoxic T-lymphocytes Procedure: flow cytometry Procedure: immunoenzyme technique Procedure: polymerase chain reaction |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | ADMINISTRATION OF LMP1- and LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOLLOWING CD45 ANTIBODY TO PATIENTS WITH RELAPSED EBV-POSITIVE HODGKIN'S OR NON-HODGKIN'S LYMPHOMA (ALDI) |
Estimated Enrollment: | 24 |
Study Start Date: | September 2006 |
Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
OBJECTIVES:
OUTLINE: This is a dose escalation study of LMP1- and LMP2-specific cytotoxic T lymphocytes (CTL).
Peripheral blood is collected from the patient or a donor and allogeneic or autologous dendritic cells (DC) are generated over 7 days using sargramostim (GM-CSF) and interleukin-4 (IL-4). DC are transduced with recombinant adenovirus encoding non-toxic LMP1 and LMP2 and matured with recombinant IL-4, GM-CSF, TNF-α, and prostaglandin (PGE-1) over 2 days to stimulate cytotoxic T lymphocytes (CTL). An Epstein-Barr virus (EBV)- transformed lymphoblastoid cell line is transduced with non-toxic LMP1 and LMP2 to produce CTL for infusion.
Patients receive anti-CD45 monoclonal antibody IV over 6-8 hours on days 1-4 and LMP1- and LMP2-specific CTL IV over 1-10 minutes on day 6, 7 or 8.
Blood samples are collected periodically during treatment for immune function studies, including total and differential lymphocyte count and immunophenotyping; immune function assays including analysis of frequency of T cells specific for test antigens such as cytomegalovirus or adenovirus as well as EBV using tetramer analysis, ELISPOT, or CTLp assays; cytotoxicity assays to look at specificity of response; and PCR for EBV DNA. Plasma-free anti-CD45 monoclonal antibody levels are also measured by flow cytometry 48-72 hours after final infusion of CD45 monoclonal antibody.
After completion of study treatment, patients are followed every 2 weeks for 8 weeks, at 3, 6, 9, and 12 months, and then periodically thereafter.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Meets 1 of the following criteria for relapsed disease:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Texas | |
Dan L. Duncan Cancer Center at Baylor College of Medicine | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Clinical Trials Office - Dan L. Duncan Cancer Center at Baylor 713-798-1297 | |
Methodist Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Vicky Torrano 832-824-7821 | |
Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital | Recruiting |
Houston, Texas, United States, 77030-2399 | |
Contact: Vicky Torrano 832-824-7821 |
Study Chair: | Stephen Gottschalk, MD | Baylor College of Medicine |
Study ID Numbers: | CDR0000582376, BCM-H19275, BCM-ALDI |
Study First Received: | February 1, 2008 |
Last Updated: | December 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00608478 |
Health Authority: | Unspecified |
recurrent adult Hodgkin lymphoma recurrent/refractory childhood Hodgkin lymphoma recurrent mycosis fungoides/Sezary syndrome recurrent cutaneous T-cell non-Hodgkin lymphoma recurrent adult grade III lymphomatoid granulomatosis adult nasal type extranodal NK/T-cell lymphoma Waldenstrom macroglobulinemia recurrent adult diffuse large cell lymphoma recurrent adult diffuse mixed cell lymphoma recurrent adult diffuse small cleaved cell lymphoma recurrent adult immunoblastic large cell lymphoma recurrent adult lymphoblastic lymphoma recurrent grade 1 follicular lymphoma recurrent grade 2 follicular lymphoma recurrent grade 3 follicular lymphoma |
recurrent mantle cell lymphoma extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue nodal marginal zone B-cell lymphoma recurrent marginal zone lymphoma splenic marginal zone lymphoma recurrent small lymphocytic lymphoma recurrent childhood anaplastic large cell lymphoma recurrent childhood grade III lymphomatoid granulomatosis childhood diffuse large cell lymphoma childhood immunoblastic large cell lymphoma recurrent childhood large cell lymphoma recurrent childhood lymphoblastic lymphoma childhood nasal type extranodal NK/T-cell lymphoma recurrent childhood small noncleaved cell lymphoma post-transplant lymphoproliferative disorder |
Sezary syndrome Hodgkin's disease Hodgkin lymphoma, adult Cutaneous T-cell lymphoma Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, small cleaved-cell, diffuse Sezary Syndrome Lymphoma, B-Cell, Marginal Zone Mycosis Fungoides Small non-cleaved cell lymphoma Lymphoma, large-cell, immunoblastic Antibodies, Monoclonal Lymphoma, large-cell Lymphoma, B-Cell |
Lymphomatoid granulomatosis Mycoses Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, T-Cell Lymphoma, Large-Cell, Immunoblastic Lymphoma, Large-Cell, Anaplastic Waldenstrom macroglobulinemia Hodgkin Disease Lymphoma Immunoglobulins Chronic lymphocytic leukemia Lymphoma, Large B-Cell, Diffuse Lymphomatoid Granulomatosis Immunoproliferative Disorders Leukemia, B-cell, chronic |
Neoplasms Neoplasms by Histologic Type Pathologic Processes Disease |
Immunologic Factors Immune System Diseases Physiological Effects of Drugs Pharmacologic Actions |